CHAPTER 6 Sex- and Gender-Specific Cardiovascular Diagnosis and Treatment

CWHHA ATLAS ON THE EPIDEMIOLOGY, DIAGNOSIS AND MANAGEMENT OF CARDIOVASCULAR DISEASES IN WOMEN



CATHERINE GOODENOUGH
Woman with Lived Experience
Mississauga, ON | @cathgoodenough

MONICA PARRY
MEd, MSc, NP-Adult, PhD, CCN(C)
Toronto, ON | @parryresearch

SHARON MULVAGH MD, FRCPC, FACC, FAHA, FASE Halifax, NS | @HeartDocSharon COLLEEN NORRIS
PhD, MSc, BScN, RN, FAHA,FCAHS
Edmonton, AB | @womensheart2





WELCOME & HOUSEKEEPING



To notify the presenters and moderators if you are having any technical difficulties



To ask questions through session



To check your audio settings by clicking "Test speaker and microphone"





DISCLOSURE STATEMENT

We do not have an affiliation (financial or otherwise) with a commercial organization that may have a direct or indirect connection to the content of this presentation.



CWHHA.CA

Learning Objectives

At the end of this webinar, you will be able to:

- Discuss the diagnosis for CAD, stroke, valvular heart disease, and heart failure.
- Explain pharmacologic and non-pharmacologic treatment strategies for CAD, stroke, valvular heart disease, and heart failure.
- Describe the benefits and barriers to self-management and cardiovascular rehabilitation/secondary prevention programs.





Canadian Women's Heart Health Alliance (CWHHA)

LAUNCHED IN 2018

Over 130 members!





Mission: Disseminate education and best practices re: Women's cardiovascular (CV) health among healthcare providers and women with lived experience.



Goal: Eliminate knowledge gaps in specific CV issues and develop new practice considerations in care for women, thereby improving the health of Canadian women.



CWHHA WORKING GROUPS

NATIONAL

ALLIANCE



Advocacy



Training and Education



Knowledge Translation and Mobilization



Health Systems and Policy



Sex and Gender Definitions

SEX



- Biology chromosomes at birth (female/male)
- Encompasses hormones, genes, anatomy, physiology, etc.

GENDER




- Socially influenced determination (man/woman)
- Is culturally specific and temporal





CANADIAN WOMEN'S HEART HEALTH ALLIANCE ATLAS

Epidemiology, Diagnosis, and Management of Cardiovascular Diseases in Women



- 9 unique "chapters"
- CJC Open
- Editor: Dr. M. Graham
- 1st: published April 2020
- Annual chapter updates
- "Living document"

Norris CM Mulvagh SL. CJC Open 2020





CATHERINE'S STORY



Catherine Goodenough
Retired RN, CGN(C)
Member, Advocacy Working Group
Woman with Lived Experience
Mississauga, ON | @cathgoodenough

The Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women-Chapter 6: Sex- And Gender-Specific Diagnosis and Treatment

Morice Pary, MEL, NSC, NP-Add, PIO, CONC) - Hardele GC, Van Spall, MD, MPH - Kent-Anne Mallen, PIO, MSc - Staren L, Makeigh, MD, FRCPC, FACC, FASC, FAVA - Orisitine Pachero, MD, MSc, FRCPC - Tracey, JP. Colida, RN, PIO - Marie Amiric Clavel, DVM, PRD - Shahin Jaller, MD, MRS, FRCPC - Hearther JA, Faside, PIO - Justicine Growel, MD - Mariah Harly - Jerestine AD, Picc, PIO, RN, CONC) - Area LE. Levincoun, PIO - Orisitine A. Gensalves, PIO - Coleme M, Noris, PIO, GNP, MSc, BSCM, FAVA, FCAVIS - X == - Store Isso.

Com Acums * Published: April 19, 2022 * DOI: https://doi.org/10.10165.cjco.2022.04.002

Ab

Acute Presentation

Treatment

Frimentatio

Diagnosis and Transment

Rahabilitation/Second.

Conclusions

Abstract

This chapter summarizes the sex- and gender-specific diagnosis and treatment of acute/unstable preseptiations and nonacute/stable presentations of cardiovaccutal dreades in women. Guidelines, scientific statements, systematic reviews/metaanalyses, and primary research studies related to diagnosis and treatment of coronary artery disease (CAD), cerebovascular disease (stories), valviruar heart disease (VHD), and heart failure in somen were reviewed. The evidence is summarized as a narrative and, when available, sex- and pender-specific practice and research recommendations are provided. Acute coronary arginome (ACS) presentations and emergency department delays are different in women compared to men Coronary analogoraphy remains the gold standard relate for diagnosis of bottomer (ACS) presentations are provided as the compared tomography remains the gold standard relate for diagnosis of bottomer (ACS) provided tomography, echocardiopathy, singlephoton emission comprede foreignaphy, cardiovascular imagenter resonance, coronary computed tomography angiography (CCTA)) have been shown to be useful in women, with their selection dependent upon the goal of the individualized assessment, and testing resources available. Non-coronars computed tomography (CT) and CT angiography are used to dispress stories in women. Although time appears to be excepticed indirecretions the effectively of standard treatments for diverse presentations of ACS, many cardiovascular drugs and interventions lested in clinical trails were next provided supported to deverse presentations of ACS, many cardiovascular drugs and interventions lested in clinical trails were evolving about servelying about servelying about servelying and the evolving about servelying about servelying about servelying and servelying about servelying and the evolving about servelying and the evolving about servelying and servelying and access provided to evolving about servelying and access provided to a servely and access provided to evolving about servelying and



Monica Parry MEd, MSc, NP-Adult, PhD, CCN(C)

Member, Knowledge Translation and Mobilization Working Group

Associate Professor, Lawrence S. Bloomberg Faculty of Nursing, University of Toronto

Nurse Practitioner, Cardiac Program, Kingston Health

Sciences Centre

Toronto, ON | @parryresearch

CANADIAN WOM

CHAPTER 6/SEX-AND G

REVIEW | ARTICLES IN PRESS

The Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women-Chapter 6: Sex- And Gender-Specific Diagnosis and Treatment

Monica Parry, MEd, MSc, NP-Adult, PhD, CCN(C) Harriette G.C. Van Spall, MD, MPH

Kerri-Anne Mullen, PhD, MSc . Sharon L. Mulvagh, MD, FRCPC, FACC, FASE, FAHA .

Christine Pacheco, MD, MSc, FRCPC * Tracey JF. Colella, RN, PhD * Marie-Annick Clavel, DVM, PhD * Shahin Jaffer, MD, MHSc, FRCPC . Heather J.A. Foulds, PhD . Jasmine Grewal, MD . Marsha Hardy .

Jennifer A.D. Price, PhD, RN, CCN(C) Anna L.E. Levinsson, PhD Christine A. Gonsalves, PhD Devine Colleen M. Norris, PhD, GNP, MSc, BScN, FAHA, FCAHS & Show less

Open Access * Published: April 19, 2022 * DOI: https://doi.org/10.1016/j.cjco.2022.04.002

Abstract

Abstract Introduction

Acute Presentations

Diagnosis and Treatment

Non-Acute

Presentations:

Diagnosis and Treatment

Cardiovascular

Rehabilitation/Seconda ry Prevention

Conclusions


summarized as a narrative and, when available, sex- and gender-specific practice and research recommendations are provided. Acute coronary syndrome (ACS) presentations and emergency department delays are different in women compared to men. Coronary angiography remains the gold standard test for diagnosis of obstructive CAD. Other diagnostic imaging modalities for ischemic heart disease detection (e.g., positron emission tomography, echocardiography, singlephoton emission computed tomography, cardiovascular magnetic resonance, coronary computed tomography angiography [CCTA]) have been shown to be useful in women, with their selection dependent upon the goal of the individualized assessment, and testing resources available. Non-contrast computed tomography (CT) and CT angiography are used to diagnose stroke in women. Although there appears to be sex-specific differences in the efficacy of standard treatments for diverse presentations of ACS, many cardiovascular drugs and interventions tested in clinical trials were not powered to detect sex-specific differences and knowledge gaps remain. Similarly, although knowledge is evolving about sex-specific

This chapter summarizes the sex- and gender-specific diagnosis and treatment of acute/unstable presentations and nonacute/stable presentations of cardiovascular disease in women. Guidelines, scientific statements, systematic reviews/meta-

cerebrovascular disease (stroke), valvular heart disease (VHD), and heart failure in women were reviewed. The evidence is

analyses, and primary research studies related to diagnosis and treatment of coronary artery disease (CAD),

Age-Standardized CVD Deaths per 100,000 Women **Across Global Burden of Disease Regions in 2019**





NATIONAL

ALLIANCE

CWHHA.CA |



Vogel et al. 2021. Lancet. 397: 2385-2438.

CANADIAN WOMEN'S HEART HEALTH ALLIANCE ATLAS

Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women



CHAPTER 6 | SEX- AND GENDER-SPECIFIC DIAGNOSIS AND TREATMENT

CORONARY ARTERY DISEASE (CAD)

A higher prevalence of non-obstructive CAD in women results in lower diagnostic accuracy with conventional testing. Coronary angiography remains the gold standard test for diagnosis of CAD in women.

Women should be managed with the same guideline-directed pharmacologic therapies as men in the acute setting, recognizing that there are sex-unique and life-course precautions regarding dosing.

Women presenting with ST elevation myocardial infarction (STEMI) or non-STEMI with high-risk features should have early invasive stratification by coronary angiography with an intention to perform revascularization.

CEREBROVASCULAR DISEASE

Stroke affects women across their life course, although the risks are higher during pregnancy, menopause, and in later years. Symptoms (e.g., tingling, numbness, short duration visual or speech disturbances) may present as less serious in women, potentially leading to a missed diagnosis.

Sex differences in stroke symptoms and door-to-imaging times result in inappropriate treatments and/or missed opportunities for treatment within the recommended therapeutic time window for women.

VALVULAR HEART DISEASE

Current guidelines for the diagnosis and management of patients with valvular heart disease (VHD) have limited sex-specific recommendations, despite numerous sex-specific evaluations and outcomes having been reported.

HEART FAILURE

Women are less likely than men to receive certain heart failure medications, such as angiotensin-converting enzyme inhibitors.

Treatment of heart failure with preserved ejection fraction (HFPEF) includes treatment of comorbid conditions, with a need for more clinical trials stratified by sex.

CARDIOVASCULAR REHABILITATION

All women should be referred for cardiovascular rehabilitation/ secondary prevention (CR/SP) after an acute cardiovascular event. However, women are less likely than men to be referred to or participate in CP/SP programs.

Women's reduced participation in CR/SP programs is due to an array of demographic, socioeconomic, medical, and societal challenges faced by women.


Evaluation and Diagnosis of Acute Chest Pain

Cardiac
Possibly Cardiac
Noncardiac



Gulati et al, 2021, JACC, 78(22).





KEY MESSAGE # 1

Women who present with acute chest pain are at risk for underdiagnosis, and potential cardiac causes should always be considered.





Obtain a history that emphasizes accompanying symptoms that are more common in women with ACS.



A focused cardiovascular exam is needed.



An ECG should be obtained and reviewed within 10 minutes of arrival to ED.



cTn should be measured as soon as possible after presentation.
Consider sex-specific hs cTn.

Recommendations for Acute Chest Pain


- 1. If initial ECG is nondiagnostic, serial ECGs to detect potential ischemic changes should be performed.
- 2. If initial ECG is consistent with an ACS, then treat according to STEMI and NSTE-ACS guidelines.
- If there is an intermediate-to-high clinical suspicion for ACS when initial ECG is nondiagnostic, serial ECGs V7 to V9 can assist to rule out posterior MI.







Other Cardiac Testing Considerations



The choice of imaging depends on the clinical question of importance, to either a) ascertain the diagnosis of CAD and define coronary anatomy or b) assess ischemia severity among patients with an expected higher likelihood of ischemia with an abnormal resting ECG or those incapable of performing maximal exercise.

KEY MESSAGE # 2

Coronary angiography is the gold standard test for diagnosis of obstructive CAD

Additional Noninvasive Diagnostic Testing:



Exercise ECGAble to achieve ≥ 5 METs



Stress Nuclear (e.g., PET or SPECT)



Echocardiography (e.g., transthoracic, stress)



Cardiovascular Magnetic Resonance Imaging (CMR)



Coronary Computed
Tomography Angiography
(CCTA)

Should follow a clinical decision pathway.

KEY MESSAGE # 3

Various non-invasive imaging strategies are used for stable or non-acute presentations of chest pain.



Exercise treadmill testing is rapid, inexpensive, and is the most common non-invasive test for low risk women who can exercise.




IMPROVED DIAGNOSTIC AND PROGNOSTIC EVALUATION

- Integrate multiple parameters (e.g., exercise time, changes in ST-segment, presence of angina)
- Additional risk correlates are heart rate and blood pressure response and recovery

CONTRAINDICATIONS

- Abnormal ST changes on resting ECG
- · Some rhythm disturbances
- Unable to achieve ≥ 5 METs
- · Severe symptomatic aortic stenosis
- Uncontrolled heart rate or HTN

What is the Correct Diagnostic Test?



KEY MESSAGE # 4

Recommendations for the Pharmacologic Management of Women with Stable CAD.

Strong Recommendation
Conditional Recommendation
High Quality Evidence
Moderate Quality Evidence



- ASA 81MG DAILY OR CLOPIDOGREL 75MG DAILY
- DUAL ANTIPLATELET THERAPY SHOULD NOT BE USED ROUTINELY
- STATINS AS PER DYSLIPIDEMIA
 GUIDELINES
- **ACE-I OR ARB**
- BETA-BLOCKERS IF LVEF < 40%
- CALCIUM CHANNEL BLOCKERS

Recommendations for Non-Pharmacologic Management of Women with Stable CAD

Coronary artery bypass graft (CABG) surgery is considered the gold standard for revascularization for multivessel CAD with diabetes that is not amenable to PCI.

*The ISCHEMIA trial failed to show that routine invasive therapy reduced MACE compared to optimal medical therapy (23% females).





Cerebrovascular Disease (Stroke)

STROKE RISK INCREASES IN WOMEN WHO:



Are pregnant

Pregnant women are three times more likely to have a stroke as non-pregnant women of the same age.



Have preeclampsia

This dangerous condition of high blood pressure during pregnancy doubles stroke risk later in life.



Take birth control pills

These can double the risk of stroke. especially in women with high blood pressure.



Use hormone replacement therapu

It doesn't lower stroke risk if postmenopausal, as once thought.



Have migraines with aura and smoke

Strokes are more common in women who have migraines with aura and smoke; compared with other women.




Have atrial fibrillation

This guivering or irregular heartbeat can increase stroke risk fivefold.

STROKE SYMPTOMS: WOMEN VS. MEN

Men and women share a common set of stroke symptoms. But women also can experience more subtle warning signs.



Source: American Stroke Association; Gender Medicine; Journal of Neuroscience Nursing

Published May 31, 2019 | © Copyright 2020 American Heart Association, Inc.

By American Heart Association News



KEY MESSAGE # 5

Stroke affects women across their life course. Risks are highest during pregnancy, menopause and in later years.

Recognize nontraditional symptoms of tingling, numbness, visual/speech disturbances.



Heart Failure



- Second cause of hospitalization, third cause of death in women
- Symptoms
 - Shortness of breath, fatigue, swelling
- Underlying mechanisms
 - Heart is too stiff (HFpEF) more frequent in women (55%)
 - Heart is too weak (HFrEF) (29% women)

Causes


- Previous heart attacks (ischemic)
- Toxic: alcohol, illicit drugs, chemotherapy
- Valvular heart disease
- Genetic
- Cardiomyopathies





CWHHA.CA

Diagnostic Algorithm for Heart Failure

NT-proBNP sex-specific cutoffs are not recommended.







McDonald et al, 2021, CJC, 37: 531-546.

NATIONAL

ALLIANCE



KEY MESSAGE # 6

Women with heart failure report lower quality of life than men.

Women less frequently receive ACE-Is and MRAs compared to men.




Women are underrepresented in clinical trials and current guidelines are lacking in sex-specific recommendations.





Valvular Heart Disease




Changes in left ventricular and left atrial dimensions and/or mass indexed to body surface area observed after mitral regurgitation surgery in men (green bars) and women (pink bars). Note the similar reverse remodeling in both sexes. BSA = body surface area; LAD = left atrial diameter; LV = left ventricle; LVEDD = left ventricular end-diastolic diameter; LVESD = left ventricular end-systolic diameter. Data are presented by mean (SD). Mantovani et al, 2016, JACC: Cardiovascular Imaging, 9(4): 388-396.





Cardiovascular Rehabilitation/Secondary Prevention



"A Woman Survivor's Perspective—With a cardiac diagnosis, there is Loss. Fear. Denial. Anger. There is deep to the core existential uncertainty and angst. One is shaken with the reality of one's mortality. The physical healing and recovery is a task on one level. However, this must be accompanied by the emotional and spiritual re-piecing together of one's 'new life'.

The challenge of a cardiac rehab program is to include not just exercise and educational components, but also to provide emotional, psychological and social supports to help heal the fragile and traumatized psyche, in order to give the woman her life—with hope, balance, and perspective—back."

—M. Hardy, Woman With Lived Experience, Canadian Women's Heart Health Alliance (personal communication, June 16, 2019)

Heart & Stroke 2018 Heart Report, 2018.



In Summary

- CVD is the leading cause of death in women.
- Since 2017, CV mortality has increased in Canada.
- Younger women are having heart attacks and more women have non-obstructive CAD.
- Stroke affects women across the life course.
- Current guidelines (e.g., valvular heart disease, heart failure) have limited sex-specific recommendations.
- All women should be referred for CV rehabilitation/secondary prevention.









WE WANT TO HEAR FROM YOU.

Questions, Comments...





THANK YOU!



EVALUATION

Please complete the evaluation form after the webinar.

For more information visit **CWHHA.CA**